Abcuro, Inc

Abcuro, Inc. is a clinical-stage biotechnology company focused on developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer. Their approach involves precisely modulating highly cytotoxic T cells, which are implicated in the pathology of these diseases. Their lead program, ulviprubart (ABC008), is a monoclonal antibody designed to selectively deplete highly cytotoxic T cells by targeting killer cell lectin-like receptor G1 (KLRG1). ABC008 is currently in clinical trials for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia (T-LGLL), both conditions lacking effective treatment options.

Beyond ABC008, Abcuro is also advancing ABC015, a KLRG1-blocking antibody in preclinical development for immune-oncology applications. By disrupting the interaction between KLRG1 and its ligands on cancer cells, ABC015 aims to activate highly cytotoxic T cells and NK cells to potentially trigger natural anti-tumor activity. Abcuro's commitment to developing innovative therapies for unmet needs in autoimmune disease and cancer is reflected in their experienced and dedicated team, their ongoing clinical trials, and their recent successful Series B financing.

Abcuro does not provide information about job flexibility on their website or in the job postings.

Abcuro is a clinical-stage biotechnology company dedicated to developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer. Their focus is on precisely modulating highly cytotoxic T cells, aiming to address unmet needs in these challenging areas. Their lead program, ulviprubart (ABC008), is currently in clinical trials for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia (T-LGLL), demonstrating their commitment to bringing meaningful therapeutic advances to patients.

Abcuro fosters a collaborative and passionate culture that prioritizes innovation and making a difference for patients. The company's website emphasizes the importance of a dedicated and experienced team that is deeply curious, analytical, and driven to bring meaningful therapeutic advances. This suggests a workplace where team members are encouraged to share their ideas, work together to achieve common goals, and are motivated by a desire to contribute to the development of groundbreaking treatments for autoimmune diseases and cancer.

Abcuro is dedicated to building a diverse, equitable and inclusive workplace, reflecting their commitment to bringing meaningful therapeutic advances to patients. The company actively seeks to assemble a team of experienced and dedicated individuals who share a passion for their mission. Abcuro's team is deeply curious, analytical, and driven to make a difference for patients, believing that a diverse perspective leads to innovative solutions and better outcomes.